FindTrial
Sign In

The ED50 and ED95 of Oliceridine Combined with Ciprofol for Suppressing Gastroscope Insertion Response

The ED50 and ED95 of Oliceridine Combined with Ciprofol for Suppressing Gastroscope Insertion Response

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116676
Enrollment
Unknown
Registered
2026-01-13
Start date
2026-01-19
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Experimental group:Oliceridine (modified sequential method) + ciprofol

Sponsors

Chinese People's Liberation Army Northern Theater Command General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. ASA Level I or II. 2.Age range: 18-60 years old. 3.BMI 18.5-27.9 kg/m^2. 4.Perform general anesthesia and painless gastroscopy. 5.Signed informed consent form.

Exclusion criteria

Exclusion criteria: 1. Upper gastrointestinal bleeding or significant abnormalities in coagulation function. 2.Severe organ dysfunction. 3. Expected difficulty with airway. 4.Long term use of psychotropic drugs or cognitive impairment. 5.Allergies or contraindications to the medication used in this anesthesia plan. 6.Patients with gastroscopy examination lasting more than 3 minutes.

Design outcomes

Primary

MeasureTime frame
Body movement response;Blood pressure; Heart rate;—

Secondary

MeasureTime frame
Dizziness;Nausea and vomiting;Pulse oximetry;Sedation related adverse events;—

Countries

China

Contacts

Public ContactLi Lin

Chinese People's Liberation Army Northern Theater Command General Hospital

lilinslashofmine@qq.com+86 155 2443 9886

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026